Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate

Johnson & Johnson (NYSE:JNJ) ranks among the best most active stocks to buy right now. On March 13, Johnson & Johnson (NYSE:JNJ) revealed results from a Phase 1 study of an innovative intravesical drug-releasing mechanism with erdafitinib (Erda-iDRS) in patients with non-muscle-invasive bladder cancer who had specific fibroblast growth factor receptor mutations.

Pixabay/Public Domain

According to the company, the trial met its major safety goals. The intermediate-risk sample of 62 patients had an 89% complete response rate, with a median length of 18 months.

Johnson & Johnson (NYSE:JNJ) also stated on March 12 that the FDA had approved its TECNIS PureSee IOL, an expanded depth of focus intraocular lens for cataract surgery. The lens is associated with JNJ’s TECNIS portfolio, which also includes the TECNIS Odyssey and TECNIS Eyhance IOLs. The company stated that millions of patients around the world receive TECNIS lenses each year as part of their cataract treatment.

Johnson & Johnson (NYSE:JNJ) is a diversified healthcare company. It operates through three main segments: Innovative Medicine, MedTech, and Consumer Health. Its product range includes pharmaceuticals and medical devices, as well as widely recognized consumer brands.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.